| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:RET-IN-13
CAS:2684258-54-4
Package:1removed
|
3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[4-[(4-ethyl-1-piperazinyl)methyl]-2-fluoro-5-(trifluoromethyl)phenyl]- manufacturers
- RET-IN-13
-
- $2780.00
-
2026-05-11
- CAS:2684258-54-4
- Purity:
- Supply Ability: 10g
|
| | 3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[4-[(4-ethyl-1-piperazinyl)methyl]-2-fluoro-5-(trifluoromethyl)phenyl]- Basic information |
| | 3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[4-[(4-ethyl-1-piperazinyl)methyl]-2-fluoro-5-(trifluoromethyl)phenyl]- Chemical Properties |
| Boiling point | 701.9±60.0 °C(Predicted) | | density | 1.301±0.06 g/cm3(Predicted) | | pka | 12.10±0.70(Predicted) |
| | 3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[4-[(4-ethyl-1-piperazinyl)methyl]-2-fluoro-5-(trifluoromethyl)phenyl]- Usage And Synthesis |
| Uses | RET-IN-13 (compound 1), a quinoline compound, is a potent RET inhibitor with IC50s of 0.5 nM, 0.9 nM for RET (WT) and RET (V804M), respectively. RET-IN-13 has the potential for tumors or intestinal diseases related to abnormal activation of RET research[1]. | | in vivo | RET-IN-13 (compound 1; 0.5 mpk; iv) has a T1/2 of 6.93 hours, a CL of 2.68 mL/min·kg, and a Vdss of 1.52 L/kg for male mice[1].
RET-IN-13 (2.5 mpk; po) has a T1/2 of 5.16 hours, Cmax of 0.958 μM and an AUC of 12477 μM·hr for male mice[1].
| | References | [1] Jiansong Wang, et al. Quinoline compounds. WO2021164742A1. |
| | 3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[4-[(4-ethyl-1-piperazinyl)methyl]-2-fluoro-5-(trifluoromethyl)phenyl]- Preparation Products And Raw materials |
|